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Very late relapses in glioblastoma long-term survivors
Abstract
Long-term survival of patients with histologically confirmed glioblastoma is a rare event with figures in
the range of 2-3% for 5-year survival (Scott et al. in Ann Neurol 46:183-188, 1999; McLendon and
Halperin in Cancer 98:1745-1748, 2003; Krex et al. in Brain 130:2596-2606, 2007). Prognosis and
further clinical course of these patients beyond 5 years after diagnosis are in essence unknown with only
anecdotal reports of patients surviving for 10 years or more (Salvati et al. J Neurooncol 36:61-64, 1998).
We here report on the extended follow-up (mean, 139.4 months) of a cohort of glioblastoma long-term
survivors. Very late relapses occurred in many patients even after more than 10 years of
progression-free survival.
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Abstract 
Long-term survival of patients with histologically confirmed glioblastoma is a rare 
event with figures in the range of 2-3% for 5 year survival.1,2,3 Prognosis and further 
clinical course of these patients beyond 5 years after diagnosis are in essence 
unknown with only anecdotal reports of patients surviving for 10 years or more.4 We 
here report on the extended follow-up (mean, 139.4 months) of a cohort of 
glioblastoma long term survivors. Very late relapses occurred in many patients even 
after more than 10 years of progression-free survival. 
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It has been suggested that glioblastoma is not the leading cause of death in patients 
that have survived for more than 10 years after diagnosis.4 We have previously 
reported a comprehensive analysis of the clinical outcome of 10 patients who had 
survived 5 years from the diagnosis of glioblastoma confirmed by neuropathological 
reassessment with a mean follow-up of 93.2 months (range, 60 to 120 months) 5. At 
that time, one patient had died 69 months after diagnosis, one other patient was 
receiving treatment for recurrent disease 106 months after diagnosis, while 8 patients 
were free of recurrence 60 – 120 months after diagnosis.  Notably, among these 10 
patients, who had completed primary therapy, no recurrences had occurred later than 
three years after diagnosis. Therefore, the possibility of a definite cure for some of 
these patients who were free of progression for almost 10 years was entertained. In 
support of this, a previous study suggested that death from recurrent glioblastoma was 
unusual in patients who had survived for more than 5 years 4. Here, we briefly report a 
further survival analysis of our cohort after a mean follow-up of 139.4 months (range 
102 to 164 months). This cohort consisted of younger than average patients in 
predominantly excellent clinical condition. Gross total resections had been achieved 
in all but one of the 10 patients. All patients had received radiotherapy and adjuvant 
nitrosourea-based chemotherapy. A total of 4 patients of the 9 patients alive at the 
previous analysis have died during the extended follow-up. Three of these patients 
died from recurrent tumor. One patient (no. 4) died from leukoencephalopathy-
associated complications without evidence of tumor progression and one patient (no. 
5) was already deceased at the time of our previous analysis. Details concerning the 
occurrence of relapses and their treatment are displayed in table 1. Individual 
progression-free survival curves are shown in figure 1 . Notably, very late relapses 
occurred in three patients after 118, 124 and 126 months of progression-free survival. 
Thus, from the original cohort of 10 patients only 3 remain free from recurrence after 
4, Bähr et al. 
 
the extended follow up of more than 10 years (123, 134 and 145 months for patients 
8, 7 and 1, respectively). These patients have done very well, however. Patient one 
from the original series, a farmer, still maintains his small farm and serves on the 
council of the local town. He has mild impairment of emotional control but no focal 
deficits. Patient seven has given birth to two healthy children 52 and 84 months from 
the diagnosis of glioblastoma and continues to work part-time. She has suffered from 
repetitive vestibular and cochlear injury on the tumor side, possibly as a consequence 
of radiation injury and is otherwise unremarkable. Patient eight has also given birth to 
a healthy child 67 months from the diagnosis of glioblastoma and continues to work 
part-time. She suffers from incomplete hemianopia since surgery. The remaining 
patient has been diagnosed with tumor  recurrence and is currently awaiting surgery. 
She has good cognitive function, but is wheel-chair bound due to postoperative 
hemiparesis. In summary, the extended follow-up of glioblastoma long-term survivors 
reveals that excellent clinical courses beyond 10 years after the diagnosis are possible, 
but also cautions that the risk of tumor recurrence remains high. Thus, it appears 
questionable whether the rare cases with longer progression-free survival can be 
considered cured. 
While the current routine at most institutions is to extend the control intervals to 6 
months and one year after 2 years and 5 years of survival, respectively, our results 
challenge this procedure. Though it remains unproven that earlier diagnosis of 
recurrence will result in better chances to achieve tumor control, the case histories of 
some of our patients are suggestive of such a benefit. In patients 3, 4, 5, and 6 
recurrences without clinical symptoms were detected by imaging, and a gross total 
resection was achieved in all of them. In patient 10, a seizure heralded recurrence 
although the patient had no longer been in routine follow-up, and a gross total 
resection was also achieved. Patient 9, however, had refused further imaging and after 
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124 months was admitted for progressive personality change and hemiparesis on the 
left side. MR imaging revealed a large recurrent tumor in the right frontal lobe with 
extension into the basal ganglia. Only a decompressive partial resection was feasible 
and the patient died 3 months after the diagnosis of recurrence.  
In conclusion, very late relapses pose a serious threat for glioblastoma long-term 
survivors and call for continuous vigilance. The maintenance of a tight control 
schedule even in patient surviving for more than 10 years should be considered. 
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Table 1 
 Primary Therapy  
Patient/age/sex KPS, % Surgery Irradiation, Gy Chemotherapy
Occurrence of 
relapses, months Treatment at recurrence 
Survival, 
months 
Status 
1/42/M        90 GTR 54 ACNU/Ara-C - - 145 alive 
2/35/F       50 GTR 54 ACNU/VM26 126 -1 128 alive 
3/44/F        80 GTR 40/622 ACNU/VM26 26 PR+PCV 109 deceased 
        
        
        
       
77 PCV  
93 TMZ  
106 none  
4/42/M 90 GTR 60 ACNU/Ara-C 27 GTR+PCV 152 deceased3 
5/54/M        90 GTR 60 ACNU/VM26 34 GTR 69 deceased 
        
        
        
46 PR+TMZ/Gem  
62 PR+PCV  
          67 none    
6/52/F 90 GTR 60 None 17 GTR+PCV 102 alive 
          28 GTR+PCV    
7/25/F        100 GTR 60 ACNU/VM26 - - 134 alive 
8/30/F        90 GTR 60 ACNU/VM26 - - 123 alive 
9/38/M        100 GTR 60 ACNU/Ara-C 124 PR+ACNU 127 deceased 
          126 none    
10/45/F        90 Biopsie 54 ACNU 118 PR+TMZ 138 deceased 
          132 Imatinib/Hydroxyurea    
 
1 resection planed, 2 whole-brain radiotherapy plus tumor boost, 3 patient died from leukoencephalopathy without evidence of tumor progression, 
KPS=Karnofsky performance score, GTR=gross total resection, ACNU=nimustine, Ara-C=cytarabine, VM26=teniposide, PR= partial resection, PCV= 
procarbazine, lomustine and vincristine, TMZ=temozolomide, Gem=gemcitabine 
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Figure legend 
Figure 1: Individual progression-free survival curves in long-term surviving 
glioblastoma patients. Recurrences are indicated by a step downward in the individual 
curve. The numbers correspond to the patient numbers in the original report. * Patient 
alive, g patient deceased, # patient died from leukoencephalopathy without evidence of 
tumor progression. 

